# Fatty Liver Screening in Type 2 Diabetes: What the ADA Recommends

What the 2026 ADA guidelines say about fatty liver screening with type 2 diabetes, when liver stiffness tests may follow FIB-4, and what models found about screening costs.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/should-you-be-screened-for-fatty-liver-with-diabetes
Updated: 2026-11-15
Published: 2026-09-16

[← Research](https://buythisglp.com/research)

Evidence

# Fatty Liver Screening in Type 2 Diabetes: What the ADA Recommends

The American Diabetes Association recommends starting with FIB-4 to assess liver-scarring risk in adults with type 2 diabetes, even when liver enzymes are normal.

Editorial profile: [Carla Medina](https://buythisglp.com/authors/carla-medina)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20265 min readUpdated November 2026

Modeled screening pathways across six countries · Multi-step non-invasive tests · From cost-saving with better outcomes to £18,572 per QALY. · 90–100% modeled probability of cost-effectiveness. · Strategies using liver biopsy · Modeled pathways cost more and led to worse outcomes. · The model compared hypothetical pathways with no screening. · Actual costs and outcomes depend on the setting.

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   The 2026 American Diabetes Association standards recommend using FIB-4 to assess liver-scarring risk in adults with type 2 diabetes, even when liver enzymes are normal.
-   A higher-risk result can lead to a liver stiffness scan, an enhanced liver fibrosis blood test, or specialist evaluation.
-   Economic models generally favored starting with noninvasive tests under the assumptions they tested. Those results reflect health-system costs and projected outcomes.

## What current guidance recommends

In type 2 diabetes, the American Diabetes Association recommends assessing the risk of liver scarring related to metabolic dysfunction-associated steatohepatitis (MASH), including when liver enzymes are normal. MASH is the form of metabolic dysfunction-associated steatotic liver disease (MASLD) that involves liver inflammation and injury. The usual starting point is FIB-4, a score calculated from age, two liver enzymes and a platelet count[\[6\]](https://buythisglp.com/research/should-you-be-screened-for-fatty-liver-with-diabetes#ref-6).

The ADA recommends further assessment when FIB-4 is elevated. The usual next test is transient elastography, a scan that measures liver stiffness. The enhanced liver fibrosis (ELF) blood test is an alternative when a scan is unavailable. Age and other risk factors can affect how clinicians interpret the score. A higher-risk result can lead to specialist evaluation, and a specialist may still consider a biopsy in selected cases [\[6\]](https://buythisglp.com/research/should-you-be-screened-for-fatty-liver-with-diabetes#ref-6) [\[7\]](https://buythisglp.com/research/should-you-be-screened-for-fatty-liver-with-diabetes#ref-7).

## What screening studies found

In a prospective San Diego study of adults aged 50 or older with type 2 diabetes, 501 met eligibility criteria and 493 had enough imaging data for analysis. Among those 493, 322 (65%) met the study’s definition of fatty liver, 69 (14%) met criteria for advanced fibrosis and 29 (6%) met criteria for cirrhosis[\[5\]](https://buythisglp.com/research/should-you-be-screened-for-fatty-liver-with-diabetes#ref-5).

A London primary-care study included 287 of 300 participants. It identified MASLD in 186, significant fibrosis due to MASLD in 50, and advanced fibrosis due to MASLD in 31. Among people whose liver stiffness met the study’s threshold for significant fibrosis (8.1 kPa or higher), FIB-4 gave a false-negative result in 38% and ELF did so in 54% at the cutoffs used. These were comparisons with a liver stiffness threshold in one cohort. They do not represent universal miss rates or the performance of a multi-step screening program [\[3\]](https://buythisglp.com/research/should-you-be-screened-for-fatty-liver-with-diabetes#ref-3).

## What the cost models estimated

The [annual spending study in type 2 diabetes](https://buythisglp.com/research/fatty-liver-annual-cost) compared claims for people with and without a recorded fatty liver diagnosis. The models below estimate what could change under different screening pathways.

A 2026 economic model compared screening pathways in the United States and five European countries. Some noninvasive pathways were projected to save money and improve health relative to no screening. Others added costs, up to £18,572 per quality-adjusted life year gained. A quality-adjusted life year is a measure that combines length and quality of life. The biopsy pathways tested in the model cost more and yielded worse projected outcomes than no screening[\[1\]](https://buythisglp.com/research/should-you-be-screened-for-fatty-liver-with-diabetes#ref-1).

Treatment price and expected health gains shape the [estimated value of semaglutide for MASH](https://buythisglp.com/research/is-semaglutide-cost-effective-for-mash). In a separate 12-country model, screening followed by intensive lifestyle intervention was cost-effective under the model’s criteria in all 12 countries. Adding semaglutide to lifestyle intervention was cost-effective in 11 [\[2\]](https://buythisglp.com/research/should-you-be-screened-for-fatty-liver-with-diabetes#ref-2).

A 2016 U.S. model reached a different result using ultrasound, biopsy and an older treatment pathway. It projected fewer cases of cirrhosis and liver-related deaths, but also 0.02 fewer quality-adjusted life years because it assumed a reduction in quality of life during treatment. Removing that assumption changed the result to $42,134 per quality-adjusted life year gained[\[4\]](https://buythisglp.com/research/should-you-be-screened-for-fatty-liver-with-diabetes#ref-4). The difference illustrates how assumptions about treatment after screening can change the result.

A screening result can lead to further evaluation

In the United States, the FDA granted accelerated approval to Wegovy injection for adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis, consistent with stages F2 and F3 [\[8\]](https://buythisglp.com/research/should-you-be-screened-for-fatty-liver-with-diabetes#ref-8). The [Wegovy liver trial guide](https://buythisglp.com/research/mash-trial-dose-and-duration) explains how researchers assessed fibrosis in that trial. A screening score on its own cannot establish eligibility for the indication.

## Frequently asked

Should adults with type 2 diabetes be screened for fatty liver?

The 2026 American Diabetes Association standards recommend an initial FIB-4 assessment for risk of liver scarring related to MASH in adults with type 2 diabetes, even if liver enzymes are normal.

What happens after a higher FIB-4 result?

Clinicians can assess risk further with a liver stiffness scan or an ELF blood test if a scan is unavailable. A higher-risk result may lead to evaluation by a liver specialist.

Is a liver biopsy needed for screening?

Current guidance starts with noninvasive tests. A liver specialist may consider biopsy in selected cases when more information is needed.

## Sources

1.  \[1\] Noureddin M, Jones C, Schattenberg JM, Romero-Gomez M, Bugianesi E, Ratziu V, et al. (2026). Screening for Metabolic Dysfunction-Associated Steatohepatitis in Adults with Type 2 Diabetes in the U.S. and 5 European Countries: A Cost-Utility Analysis JHEP Reports. [PMID 42705608](https://pubmed.ncbi.nlm.nih.gov/42705608/)
2.  \[2\] Lazarus JV, Agirre-Garrido L, Díaz LA, Danpanichkul P, Kivuyo SL, Kondili LA, et al. (2025). Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 Diabetes JAMA Network Open. [PMID 41196592](https://pubmed.ncbi.nlm.nih.gov/41196592/)
3.  \[3\] Forlano R, Stanic T, Jayawardana S, Mullish BH, Yee M, Mossialos E, et al. (2024). A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies Liver International. [PMID 37718933](https://pubmed.ncbi.nlm.nih.gov/37718933/)
4.  \[4\] Corey KE, Klebanoff MJ, Tramontano AC, Chung RT, Hur C (2016). Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis Digestive Diseases and Sciences. [PMID 26825843](https://pubmed.ncbi.nlm.nih.gov/26825843/)
5.  \[5\] Ajmera V, Cepin S, Tesfai K, Hofflich H, Cadman K, Lopez S, et al. (2023). A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes Journal of Hepatology. [PMID 36410554](https://pmc.ncbi.nlm.nih.gov/articles/PMC9975077/)
6.  \[6\] American Diabetes Association Professional Practice Committee for Diabetes (2026). Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026 Diabetes Care. [PMID 41358897](https://doi.org/10.2337/dc26-S004)
7.  \[7\] American Gastroenterological Association (2026). Clinical care pathway for the risk stratification and management of patients with MASLD American Gastroenterological Association. [Source](https://gastro.org/clinical-guidance/clinical-care-pathway-for-the-risk-stratification-and-management-of-patients-with-masld/)
8.  \[8\] U.S. Food and Drug Administration (2025). Wegovy accelerated approval for noncirrhotic MASH with moderate-to-advanced liver fibrosis FDA. [Source](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215256Orig1s024ltr.pdf)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
